Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This could get very interesting.
Date Short Volume IPIX Total Volume Percent
2021-11-08 1,953,364 3,258,505 59.95%
Come on Brilacidin!
Database Lock Completed for Innovation Pharmaceuticals’ Phase 2 Clinical Trial of Brilacidin for COVID-19
WAKEFIELD, MA / November 3, 2021 / ACCESSWIRE Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, today announced that the Company has received confirmation that hard lock of the database was completed for its Phase 2 clinical trial of Brilacidin for treatment of moderate-to-severe COVID-19 in hospitalized patients (see NCT04784897). Statistical analysis is underway, with topline results for the trial anticipated to be reported during the week of November 8, 2021.
Plus - wolf(e) = apex land predator / Mako = apex sea predator
This fictional Facebook character will be invested.
Hold tight and be right.
Go Leo & IPIX
In related news, the Company has received individual patient Expanded Access (compassionate use) requests for Brilacidin to treat critically ill COVID-19 patients who are not responding to prior therapy. Expanded Access was implemented by the FDA and Congress to address physician applications for access to potentially lifesaving drugs, prior to FDA approval, for patients in their care when available treatment options have failed. Following receipt of such requests, the Company has supplied Brilacidin to relevant hospitals for individual patient use, with the FDA granting the treating physician permission for the emergency administration of Brilacidin. In addition to Brilacidin’s antiviral profile, Brilacidin’s immunomodulatory and anti-inflammatory properties may be particularly beneficial in treating COVID-19 in hospitalized patients.
NEWS! Innovation Pharmaceuticals Provides Update on COVID-19 Clinical Trial, Compassionate Use Requests and Research into Brilacidin’s Broad-Spectrum Antiviral Properties
WAKEFIELD, MA / September 23, 2021 / ACCESSWIRE Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today provided an update on the status of its randomized, double-blind, placebo-controlled Phase 2 clinical trial of Brilacidin for the treatment of moderate-to-severe COVID-19 in hospitalized patients (see NCT04784897), as well as related news.
Based on information received from the data management and biostatistics vendors, study unblinding, analysis of the unblinded data and release of topline study results for the Brilacidin COVID-19 trial is anticipated to occur in mid-to-late October. The Company looks forward to the data to learn if Brilacidin’s multiple properties translate into meaningful clinical results, given the unmet need for COVID-19 therapeutics and ongoing pandemic.
In related news, the Company has received individual patient Expanded Access (compassionate use) requests for Brilacidin to treat critically ill COVID-19 patients who are not responding to prior therapy. Expanded Access was implemented by the FDA and Congress to address physician applications for access to potentially lifesaving drugs, prior to FDA approval, for patients in their care when available treatment options have failed. Following receipt of such requests, the Company has supplied Brilacidin to relevant hospitals for individual patient use, with the FDA granting the treating physician permission for the emergency administration of Brilacidin. In addition to Brilacidin’s antiviral profile, Brilacidin’s immunomodulatory and anti-inflammatory properties may be particularly beneficial in treating COVID-19 in hospitalized patients.
For more details on the Company's Expanded Access policy, please visit:
https://www.ipharminc.com/expanded-access-and-compassionate-use
Brilacidin in vitro antiviral research remains ongoing at multiple universities. New preliminary data from one academic laboratory show Brilacidin is active against adenoviruses—a non-enveloped virus—complementing earlier data showing potent Brilacidin inhibition of different strains of coronaviruses, alphaviruses and bunyaviruses (enveloped viruses). A paper from this lab on Brilacidin’s broad-spectrum antiviral effect in multiple virus families is being prepared. Separate scientific papers also are underway from two other academic research groups supporting Brilacidin’s antiviral properties and providing insight into Brilacidin’s mechanisms of action.
About Brilacidin and COVID-19
Very well thought out.... I also believe that finding a manufacturing partner will not be a problem. If there is money, they will come.
Go Leo & IPIX!
After B-COVID EUA Award - WHAT NEXT?
Gilead's Remdesivir scored an FDA emergency use authorization in May 2020 and a full approval in October 2020. Remdesivir generated $2.8B in 2020 and is projecting $2B-$3B in Remdesivir sales in 2021.
Regeneron's monoclonal antibody-cocktail treatment (Casirivimab and imdevimab t) was awarded an EUA on 11/21/2020, halfway through the 4Q/2020, and still rung-up $144M in U.S. government sales and added $1.6B to their 2021 revenue projections.
Lilly's monoclonal antibody-cocktail treatment (Bamlanivimab and Etesevimab) was awarded an EUA on 02/09/2021. The drugmaker made $810 million from the two drugs combined in the first quarter this year (2021) and estimates $1 billion to $1.5 billion in revenue from the treatments through 2021.
This brings us to the "WHAT NEXT"?
I cite these 3 COVID-EUA examples to show how quickly, with sufficient pharmaceutical manufacturing capacity (PMC), IPIX could generate billion$ in sales in a mere 3-12 months from the date of issuance an EUA.
IPIX has no PMC, but Leo is definitely in the "driver's seat" when it comes to lining-up manufacturing partners. Drug companies know that...in this moment...COVID-19 is the most lucrative of all indications and any way they can get into the game will probably result in hundreds of millions...if not billions for their revenues.
This is not news to Leo and, IMO, he has already been busy scouring the planet for excess PMC. Unlike the mRNA vaccines that have over 200-steps in their mfg process, my understanding is that "B" is relatively simple to make with low cost materials.
IMO, once B-COVID is awarded an EUA, Leo should, at the least, have a billion-dose PMC in place. The U.S., EU, UK, WHO and others will want to stockpile B-COVID in the same way they did remdesivir. Some of this stockpiling will be for national defense purposes. This is how Gilead made $2.8B 8 months after receiving an EUA and projected 2021 sales of $3B, all from a drug, remdesivir, that a major 5K WHO-study that found it had little to no effect on COVID-19.
B-COVID COULD GENERATE A BILLION OR MORE IN $ALES BEFORE A P-3 STARTS
People like to judge Leo from past events/happennings, but I submit my billion-dose PMC metric is a way to see if Leo is truly on top of one of the most important things that will lead to billion-dollar profits for IPIX. When (not if) B-COVID receives a EUA be sure to note Leo's comments pertaining to PMC and his plans to quickly mfg & disseminate B-COVID.
If I know Leo (and I think I do), the award of the EUA will not be a "start your engines" moment, the engines will already be running.
Another awesome post!
Go Leo & IPIX!
You bring up a good point, but, ignore the first part of my post instead of answering it.
Quote:
Have you found and reviewed animal studies done on the covid shots?
And, how long were clinical trials done?
I'm not seeing much about the above. I'd love to see links along with answers. You might even want to look at the animal studies that were done years ago for sars vaccines that were abandoned after the animal study results.
Either way, my dr believes I've already had covid a year ago when sick. And, I exercise, don't touch sugar, and take suggested supplements. My body, my choice.
I chose to work on diet and exercise in place of medications managing symptoms.
In a couple of years of covid shots given around the world we'll see long term effects of the shots. If covid is still around I suspect more will start taking them if issues don't pop up over the next year or two.
Way too go MackG! Great post. Hopefully Brilacidin can get too market and get the world back too normal.
Go Leo & IPiX!
JFM, Your post does a great job of summarizing how many people feel about the pros and cons of getting the covid vaccines. The new, and frequently used phrase, "vaccine hesitancy" infers that if an individual choses not to get one of the vaccines, or wants to wait because of the reasons you mentioned, then the implications are that you are a threat to society, ignorant, an anti-vaxer, etc. I too don't eat sugar or junk food, exercise, and supplement my diet with the recommended vitamins and minerals. The idea of mandating that people accept the jab, if that comes to pass, will be one more example of our personal freedoms being eroded. IMO.
Great post JFM!
Luckytouch... appreciate your concern...and about my reference to waiting for Brilacidin.
But, I must point out, that you are making some basic false assumptions about my experiences and basis upon which I have made my decision and how I am going forward...which by the way, I have discovered that 60% of my immediate family have also independently taken my position too (perhaps for different reasons). IMO it is up to them.
I am NOT AN ANTI-VAXER. I don't tell anyone NOT to take the vaccine. It is their personal decision. I just tell them, in kind, not to tell me what to do. I only listen to Medical/Science individuals and arguments on both sides, then make my decision, which I have.
I don't know the "cult" or "cult leader" to which you refer. If it is Tucker...I believe he is not an anti-vaxer conspiracist...but he is a Libertarian and an Anti-brainwashing and no BS independent thinker...and will not tolerate non-fact based, irrational, contradictory and hypocritical, ever changing "explanations" regarding the subject. The CDC/Fauci has proven itself, AT BEST, to be IMO totally full of Sh*t and shooting from the hip while in the pocket of BP...
So my decision is based upon listening to medical doctors and scientist on both side and combining it with my personal experience. Knowing your own body and how it reacts to prescription drugs/supplements is also critical. I know my body and the people around me...so I incorporate my own health/eco-environment into my decisions.
With that said, I have every "vulnerable" condition that has been identified as "high-risk" for Covid-19 and on top of that live and work (and continued to go to my office) on Long Island, 3 minutes from the NYC boarder line.
IMO the only questions is for me (and anyone) "how is my immune system?" and "what am I doing to support it." Coincidentally, for over 20 years, I have been taking every day, all the "right" (and "recommended to ward off Covid-19)" supplements in individual capsules (no single One-a-day BS) and in greater quantities then recommended...(depending on the supplement). Eat no sugar (or fruit) and no junk food.
I have never taken a flu shot. The last time I got the flu was 60 years ago. I can't remember the last time I got the common cold...had to be 5 years ago from getting extremely runner down.
You can conclude I am lucky...perhaps you would conclude "You might not have been exposed to someone with Covid-19??? Of course, you would be dead wrong... (no pun intended). I know of three serious cases in my office where the Covid individuals were literally in my face, in closed environments (window-less conference room) for hours...one hospitalized for two weeks on oxygen, the other 2 very difficult symptoms for over a week. None fit the Covid-19 candidate profile, except the hospitalized one was 76 yrs. old, but otherwise perfect shape (worked out at the gym 3 days a week).
Ironically the owner of my company was one of the three people was infected with Covid-19, with whom I was in direct contact, and who chastised me for not getting the vaccine "for society". I laughed and retorted...you walked around this office for a week coughing in everyone's face, sat in front of my desk and was insulted that I put a mask on (which masks scientifically could only have marginal effect since virus particle are much smaller than the mask holes) and then had me go to your house and meet for 4 hours...and only got tested 5 days later!
I do everything Drs say to keep my immune system in order, keep myself healthy with proper supplements, wash hands constantly ... for myself...which in turn, becomes "for Society" ...
Everyone has to take care of themselves in their own way...the real problem is most don't...and then follow the herd (whatever big government "experts" say)...without critical examination.
When (more like IF) the FDA goes through the process AND APPROVES the vaccines, AND REMOVES IMMUNITY granted to BP... then I will revisit the issue. But I doubt I will ever put it into my body. Why do so if my immune system is functioning quite well?
I do my part...which inures to the benefit of society...its society (via big totalitarian government...PRC types) I have to worry about Big Government (totalitarian) forcing me (and anyone) to do something against their individual good.
Agree...following the herd...and not engaging is critical thought and review can be fatal...both in health of one's body and our country...
End of story.
ps. Brilacidin, C-diff bacteria and ALS/MS/Parkinson's/Alzheimer’s connection...In Vitro experiments demonstrated destruction of C-diff (DeGrado)...and how effective would IV dosing be to wipe out C-diff in the brain ("Leaky-Gut/Leaky Brain") A corollary issue to that question is how it might also affect good bacteria in the Gut. If Brilacidin destroys C-diff completely, and some good bacteria, how quickly can good bacteria be added back into the gastrointestinal system to proliferate and keep any new C-diff at bay. Eliminating the condition of leaky gut (IPIX's UC proposed trials will no doubt look at bacteria count...good and bad) Leo signaled in PR planning and conducting CT for UC this year.
Connection of C-diff bacteria with serious neurological diseases... YouTube interview of Dr. Jay Lombard, Neurologist, by Dr. Mark Hyman (Director of Functional Medicine, Cleveland Clinic) link below:
Empiricst1, my wife and I chose not to have children's and therefore I have no opinion what people should do with their children. It is none of my business.
Go Leo & IPIX!
"I am not a drain on the health system and it pisses me off that my freedom is being taken away. I believe that everyone should have the right to do what they feel is best for themselves.."
Lily, do you consider it an infringement on freedom to require that all children are inoculated against common childhood diseases before being allowed to attend school?
I will not be taking a vaccine anytime soon. Unfortunately Canada will be enforcing the vaccine passport so if I want to travel out of the country I will eventually have to take it. I see holding out for at least a couple of more years before I am forced.
I spend a lot of time, energy, money and make sacrifices in attempts to stay metabolically healthy. I am not a drain on the health system and it pisses me off that my freedom is being taken away. I believe that everyone should have the right to do what they feel is best for themselves...
I would however take a therapeutic like Brilacidin if proven effective. We already know it is safe...
Go Leo & IPIX!
Have you found and reviewed animal studies done on the covid shots?
And, how long were clinical trials done?
There's a reason the FDA hasn't approved them yet, and the manufacturers have immunity from lawsuits. I'm not surprised many won't take them until enough testing has been done to warrant FDA approval without drug company immunity. Especially with such low % numbers of people getting seriously ill.
You’re firing on all cylinders tonight!!
Nice find! I hope Brilacidin ends up on this list… that could be enormous for Leo and ultimately us.
Go Leo & IPIX!
Great post JFM and Hungry_Ghost!
Justfactsmam Member Level Thursday, 05/06/21 09:29:45 AM
Re: Hungry_Ghost post# 358205 0
Post # of 358329
Hungry_Ghost...
Can't disagree with anything you posted. (My thoughts 2-cents in red.)
"My post had nothing to do with a individuals choice of being vaccinated or not. Your body, your choice." (Oh, how conveinent for some that when the object of the debate changes, you can tell me what to do! A correlary to "What is mine, is mine, what is yours is mine!")
"No matter how you want to digest the numbers 35% of the new cases are those vaccinated is not a insignificant number." IMO VERY SIGNIFICANT.
"The last few PRs have stated that researchers have been doing extensive work involving BRILACIDIN. It would indicate to me that the initial lab studies never stopped, have been running continuously since and are still on going." (LEO's PR have continuously run a thread regarding RBL reseach, continuing and expanding, both deeper into Covid1-9 AND BROADER into Pan-coronavirus/Alpha-viruses...one just needs to READ and believe in the veracity of the statements...which SUBSTANCE have ALL PROVEN OUT...timing not in his control )
"The researchers have obviously seen something that has caught their interest." (IMO have seen something SIGNIFICANT in BRILACIDIN...just because IPIX does not receive grants for Brilacidin does not mean RBL's and others don't receive GRANTS WHICH INCORPORATE FURTHER RESEARCH into the potential efficacy of Brilacidin for Pan-coronavirus/Alpha-viruses...which was noted in yesterday's letter to Shareholder)
"My post was for the hope that BRILACIDIN can be formulated for use as a inhaler after the upcoming successful phase 2 CV trials." (Agreed...but detractors of LEO, IPIX and BRILACIDIN...will use raising funds for that purpose as a weapon against all three..."Oh no...more dilution!" Big F'n deal ... I'm with you on it...the multiple will just get larger...Dilution is a straw-man. Getting multiple dollars more in valuation because of inhaler...will pay off in spades)
"The successful trial should bring grants, government funds, partnerships, something of monetary significance to move BRILACIDIN and IPIX forward."...(and of course EUA...and LICENSING!)
"My wish is for BRILACIDIN SI *426* to be available to everyone in a variety of forms. The quicker the better. The fact is Covid isn't going anywhere anytime soon. A BRILACIDIN nebulizer would be a great help to both the vaccinated and unvaccinated. Both will need that option." (Agreed!).
I completely disagree for all of the reasons I posted yesterday and I think there was a lot of new information within that article. I believe it was very telling and we should have a better understanding of the situation in the coming weeks/months.
I am looking forward to see the final results.
yours truly, Yeehaw!
Go Leo & IPIX!
I find the article ho-hum....Stuff we already know and besides the footnote as to the source of the information was none other than IPIX...
I stated before, I don't like these types of PR...We are beyond B is a great dug candidate"....Let's wait for the results and then shout "We have the solution".
I agree, I thought it was very informative.
Go Leo & IPIX!
I took a moment to reread this morning's Blog Update. The update contained much that was unknown and/or unconfirmed. I found the information to be very useful and hopefully impactful for those thinking of investing in Innovation Pharmaceuticals.
GLTA(Longs)
From the Update:
With enrollment in the Company’s Phase 2 trial of Brilacidin for treatment of COVID-19 proceeding toward completion and release of topline results, testing of Brilacidin at independent labs against multiple viruses is ongoing. Brilacidin has now been evaluated in vitro in 10 separate human cell lines, showing consistent and potent inhibition against coronaviruses, alphaviruses and, most recently, bunyaviruses.
Brilacidin lab results against alphaviruses are to be provided, this July, in an Oral Presentation at the American Society of Virology’s 2021 annual conference. Brilacidin lab results in Human Coronaviruses (H-CoVs) (OC43, 229E, NL63) are being prepared for peer-review submission.
Great, thanks for the heads up PJ007!
Go Leo & IPIX!
https://pubchem.ncbi.nlm.nih.gov/compound/Brilacidin
Modified on 05/01/21......hmmmmmmmmm
What is a Bunyaviridae you ask? See below.
Bunyaviridae
The Bunyaviridae are a very large family of single-strand, enveloped RNA viruses (more than 300 viruses) and consists of five genera of viruses: Orthobunyavirus, Phlebovirus, Nairovirus, Hantavirus, and Tospovirus (Tospoviruses infect only plants). They are found in and transmitted by arthropods (e.g. mosquitoes, ticks, sand flies) and rodents, and can occasionally infect humans. Several viruses of the Bunyaviridae virus family can produce mild to severe disease in human, in animals, and sometimes in both. This is the base for the requirements of handling some of these viruses in high containment (Biosafety Level 3 or even Biosafety level 4).
https://www.cdc.gov/vhf/virus-families/bunyaviridae.html
Bio-computational designed Brilacidin is a synthetic non-peptide defensin mimic drug that destabilises the viral membrane by its amphipathic & hydrophobic nature, and its immunomodulatory property influence the expression of IL-1ß, IL-6, TNF-a cytokines, and cAMP& PDE4/PDE3 pathways which are associated with bronchodilator and anti-inflammatory effects of COVID-19 disease. The smaller size, more effective antimicrobial activity, bioavailability, low enzymatic degradation and toxicity, natural and low-cost production make the Brilacidin a most potent drug against SARS-CoV-2 than the known antiviral drugs.
1.6. Defensins against SARS-CoV
The lectin-like human a defensin 5 (HD5) and HD6 peptides protect intestinal infections. Lectins are proteins or glycoproteins that specifically bind to carbohydrates present on the glycoproteins surface. 2019-nCoV S-proteins and its intestinal receptor ACE2 both are glycosylated proteins. HD5 binds to the ligand-binding domain (LBD) of ACE2 glycoproteins and masks its availability to enter the 2019-nCoV virus (Wang et al., 2019). This interruption between viral glycoproteins and cellular receptors activates the adaptive immune antigen-presenting phagocytes cells and interferes with nuclear enzymes that prevent viral cellular replication (Park et al., 2018). Human neutrophil peptide-4, bovine beta-defensin 1, HD5, HD6, rat neutrophil peptide 1 (RNP-1), RNP-2, chicken avian beta-defensin 5 (AvBD5), AvBD6, and channel catfish beta-defensin peptide have the antiviral activity against the Middle East Respiratory Syndrome Coronavirus [3]. HNP1-6, HD5-6, and HBD2-3 defensins remove the viruses by getting in the way of viral entry, membrane destabilisation, immune-modulating, downregulating receptors and ligands such as ACE2, CD4, CCR6 CXCR4, CXCL & CXCL5, lysosome fusion, inhibiting essential proteases, central dogma enzymes, and post assembly of virion particles (Park et al., 2018 [37]; Chang et al., 2005; [70].
Bio-computational designed Brilacidin is a synthetic non-peptide defensin mimic drug that destabilises the viral membrane by its amphipathic & hydrophobic nature, and its immunomodulatory property influence the expression of IL-1ß, IL-6, TNF-a cytokines, and cAMP& PDE4/PDE3 pathways which are associated with bronchodilator and anti-inflammatory effects of COVID-19 disease. The smaller size, more effective antimicrobial activity, bioavailability, low enzymatic degradation and toxicity, natural and low-cost production make the Brilacidin a most potent drug against SARS-CoV-2 than the known antiviral drugs. Dalbavancin, Telavancin, Oritavanci, and Roflumilast are other Brilacidin like drugs used for MERS, SARS, and SARS-CoV2 viral inhibitions [71]. Rhesus macaque's leukocytes express ?-defensin1 (RTD-1) and RTD-2 antimicrobial peptides in response to viral infections. HD5-6, HNP1-6, HBD2-6, and retrocyclin-2 inactivate the various enveloped and non-enveloped virion particles by interrupting virus pre and post-entry steps, chemokines, and cytokines immunomodulation, chemotaxis of immune cells [72].
https://www.sciencedirect.com/science/article/pii/S0882401021002023
Brilacidin lab results against alphaviruses are to be provided, this July, in an Oral Presentation at the American Society of Virology’s 2021 annual conference. Brilacidin lab results in Human Coronaviruses (H-CoVs) (OC43, 229E, NL63) are being prepared for peer-review submission.
With enrollment in the Company’s Phase 2 trial of Brilacidin for treatment of COVID-19 proceeding toward completion and release of topline results, testing of Brilacidin at independent labs against multiple viruses is ongoing. Brilacidin has now been evaluated in vitro in 10 separate human cell lines, showing consistent and potent inhibition against coronaviruses, alphaviruses and, most recently, bunyaviruses.
Bio-computational designed Brilacidin is a synthetic non-peptide defensin mimic drug that destabilises the viral membrane by its amphipathic & hydrophobic nature, and its immunomodulatory property influence the expression of IL-1ß, IL-6, TNF-a cytokines, and cAMP& PDE4/PDE3 pathways which are associated with bronchodilator and anti-inflammatory effects of COVID-19 disease. The smaller size, more effective antimicrobial activity, bioavailability, low enzymatic degradation and toxicity, natural and low-cost production make the Brilacidin a most potent drug against SARS-CoV-2 than the known antiviral drugs.
There is some very strong language in this release.
Go Leo & IPIX!
Journal Article on Defensins Highlights Brilacidin’s Potential as a Broad Spectrum Antiviral
Innovation wanted to bring to the attention of shareholders a recent review article that supports defensins as a source of potential therapeutics against viral infections.
Solanki SS, Singh P, Kashyap P, Sansi MS, Ali SA.
“Promising role of defensins peptides as therapeutics to combat against viral infection.”
Microb Pathog. 2021 Apr 29:104930. doi: 10.1016/j.micpath.2021.104930. Epub ahead of print. PMID: 33933603.
https://www.sciencedirect.com/science/article/pii/S0882401021002023
As the article conveys, newer mechanistic insights are elucidating the intrinsic and multi-faceted abilities of defensins—a type of small antimicrobial peptide—to confer protection against many types of viruses.
Brilacidin, a defensin-mimetic designed and optimized to capture the biological properties of naturally occurring defensins, was highlighted in the article:
Bio-computational designed Brilacidin is a synthetic non-peptide defensin mimic drug that destabilises the viral membrane by its amphipathic & hydrophobic nature, and its immunomodulatory property influence the expression of IL-1ß, IL-6, TNF-a cytokines, and cAMP& PDE4/PDE3 pathways which are associated with bronchodilator and anti-inflammatory effects of COVID-19 disease. The smaller size, more effective antimicrobial activity, bioavailability, low enzymatic degradation and toxicity, natural and low-cost production make the Brilacidin a most potent drug against SARS-CoV-2 than the known antiviral drugs.
With enrollment in the Company’s Phase 2 trial of Brilacidin for treatment of COVID-19 proceeding toward completion and release of topline results, testing of Brilacidin at independent labs against multiple viruses is ongoing. Brilacidin has now been evaluated in vitro in 10 separate human cell lines, showing consistent and potent inhibition against coronaviruses, alphaviruses and, most recently, bunyaviruses.
Brilacidin lab results against alphaviruses are to be provided, this July, in an Oral Presentation at the American Society of Virology’s 2021 annual conference. Brilacidin lab results in Human Coronaviruses (H-CoVs) (OC43, 229E, NL63) are being prepared for peer-review submission.
Great post JFM!
Peter is absolutely correct:
"What possible blame can you find with IPIX for the slower than expected enrollment? Once the trial parameters and sites are fixed, things are completely out of IPIX hands."
It is easy to post: "It's not completely out of their hands as far as I can tell"... (ah...another Strawman setup!)
...without stating exactly what is in IPIX/LEO's "hands"...the statement is meaningless since once IPIX engages the U.S. Supervising CRO...CRO picks Clinical Trial Sites and sets those selected sites up, with their counter-part local CRO organization (if not in U.S.), then shipping exact and specified supplies set forth and approved by FDA in the protocol, then expediting the delivery of Brilacidin to the local CRO/Hospital site...then WAITING FOR PROSPECTIVE CANDIDATES, per protocol, and soliciting and selecting candidates with Hospital site Med Staff/Local CRO.
So wondering exactly where Leo/IPIX has control over expected enrollment and recruitment of candidates?
THE U.S. CRO runs the trials for IPIX....all sites report to and interact with the Supervising CRO...not LEO or IPIX... Supervising CRO reports on behalf of IPIX to ClinicalTrials.org as per direction and authorization of IPIX!
The pace of Clinical Trials is strictly "Patient Dependent", and not any patient, but Patient fitting the Clinical Trial Protocol of Moderate to Severe Covid-19 requiring hospitalization AND who have not taken the vaccine. In U.S. with millions taking the vaccines...millions are disqualified. Russian therefore becomes the obvious Site of Choice...if Protocol Patients arrive first in Russia...
SO we are expected to believe that the U.S. Trial Supervising CRO LEAD does not have the appropriate company/executive contact # and does not have Leo's cell phone to reach Leo 24/7?... IMO Beyond ridiculous supposition.
And who has to speak Russian? Does anyone believe that Russian CROs could build a credible Western BP CRO business without boots on the ground local CRO not speaking English to their counterparts?*
In 1969, at 19, as a merchant marine, I was Leningrad (now St. Petersburg) and as I and other like-age guys disembarked from our ship, were met by a half a dozen
How many people are dying of lung cancer from smoking - approximately 130,00 each year in US? Alcoholism - approximately 95,000 each year in US? Obesity - approximately 300,000 each year in the US? We don't hear about that in the media, why you ask, because it will not convince those participating in these behaviors to stop.
I am not trying to minimize your comments I am simply pointing out that whatever causes the most fear gets the biggest budget. At your expense might I add.
I hope Brilacidin can work against COVID and its variants and I hope it is soon.
Go Leo & IPIX!
"It is a pretty huge excuse to generate lots of spending."
Lily, approaching 600,000 dead still seems like a big del to me.
I don't have that fear. I believe the media/governments will continue to make COVID an excuse for everything over the next several years. It is a pretty huge excuse to generate lots of spending.
My main concern is by the time they have come out with great results the virus will be gone.
Agreed! Unfortunately this not happening as fast as I would like but Brilacidin keeps making positive progress which is all I ever want.
Brilacidin is a serious contender for the treatment COVID and its variants and I can't wait for the final results.
Go Leo & IPIX!
Innovation Pharma Surpasses 50 Percent Enrollment in Phase 2 Clinical Trial of Brilacidin for COVID-19
• >60 patients have been randomized in the Company’s ~120-patient Phase 2 COVID-19 clinical trial
• With COVID-19 cases rising worldwide as the coronavirus continues to mutate, the need is greater than ever to develop novel broad spectrum antivirals of the future
WAKEFIELD, MA – April 28, 2021 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced that enrollment has surpassed 50 percent of the total targeted number of randomized trial participants (~n=120) in its double-blind, placebo-controlled Phase 2 clinical trial of Brilacidin for treatment of moderate-to-severe COVID-19 in hospitalized patients (see NCT04784897).
Brilacidin is the only non-peptidic defensin-mimetic drug candidate in the world currently in a clinical trial as a treatment for SARS-CoV-2, the coronavirus responsible for COVID-19. Additionally, Brilacidin has shown potent inhibition in vitro against different strains of coronaviruses and alphaviruses (with lab testing against other virus families also underway), supporting Brilacidin’s potential to be developed as a broad spectrum antiviral.
“Achieving over 50 percent trial enrollment represents an important milestone as we advance Brilacidin for treatment of COVID-19,” commented Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. “We are hopeful Brilacidin will emerge not only as an effective COVID-19 therapeutic, but also as a desperately needed broad spectrum antiviral. With the world experiencing a record number of new COVID-19 cases, including nearly 1 million new infections in India across a 3-day period, we remain dedicated to bringing to market a novel antiviral to help ease patient suffering. We look forward to completing our COVID-19 clinical trial and releasing topline results.”
Linked below are recent articles published in the journal Nature. Both reinforce the need for developing novel antiviral drugs, such as Brilacidin, to help address the current COVID-19 crisis, as well as to be prepared to confront future pandemics.
• Funders, now is the time to invest big in COVID drugs (nature.com): Vaccine development has been a resounding success. But the medicine cabinet should have been better stocked.
• The race for antiviral drugs to beat COVID — and the next pandemic (nature.com): Despite dire warnings, a stockpile of ready compounds to fight viral pandemics was sorely lacking. Can drugmakers finally do the right thing?
About Brilacidin and COVID-19
Innovation Pharma is developing Brilacidin for COVID-19 under Fast Track designation from the U.S. Food and Drug Administration (FDA), and currently is enrolling patients in a Phase 2 clinical trial of Brilacidin for treatment of moderate-to-severe COVID-19 in hospitalized patients (see NCT04784897). Upon recently completing a scheduled review of interim safety data from the trial, an independent Data Monitoring Committee (DMC) recommended increasing the dosing regimen of Brilacidin from 3 days to 5 days of treatment, which may maximize therapeutic benefits and provide a comparison with 5-day remdesivir (Veklury™), currently the only FDA-approved treatment for COVID-19. The annual global antiviral drug market is estimated to reach $44 billion by 2026.
Innovation Pharma Surpasses 50 Percent Enrollment in Phase 2 Clinical Trial of Brilacidin for COVID-19
• >60 patients have been randomized in the Company’s ~120-patient Phase 2 COVID-19 clinical trial
• With COVID-19 cases rising worldwide as the coronavirus continues to mutate, the need is greater than ever to develop novel broad spectrum antivirals of the future
WAKEFIELD, MA – April 28, 2021 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced that enrollment has surpassed 50 percent of the total targeted number of randomized trial participants (~n=120) in its double-blind, placebo-controlled Phase 2 clinical trial of Brilacidin for treatment of moderate-to-severe COVID-19 in hospitalized patients (see NCT04784897).
Brilacidin is the only non-peptidic defensin-mimetic drug candidate in the world currently in a clinical trial as a treatment for SARS-CoV-2, the coronavirus responsible for COVID-19. Additionally, Brilacidin has shown potent inhibition in vitro against different strains of coronaviruses and alphaviruses (with lab testing against other virus families also underway), supporting Brilacidin’s potential to be developed as a broad spectrum antiviral.
“Achieving over 50 percent trial enrollment represents an important milestone as we advance Brilacidin for treatment of COVID-19,” commented Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. “We are hopeful Brilacidin will emerge not only as an effective COVID-19 therapeutic, but also as a desperately needed broad spectrum antiviral. With the world experiencing a record number of new COVID-19 cases, including nearly 1 million new infections in India across a 3-day period, we remain dedicated to bringing to market a novel antiviral to help ease patient suffering. We look forward to completing our COVID-19 clinical trial and releasing topline results.”
Linked below are recent articles published in the journal Nature. Both reinforce the need for developing novel antiviral drugs, such as Brilacidin, to help address the current COVID-19 crisis, as well as to be prepared to confront future pandemics.
• Funders, now is the time to invest big in COVID drugs (nature.com): Vaccine development has been a resounding success. But the medicine cabinet should have been better stocked.
• The race for antiviral drugs to beat COVID — and the next pandemic (nature.com): Despite dire warnings, a stockpile of ready compounds to fight viral pandemics was sorely lacking. Can drugmakers finally do the right thing?
About Brilacidin and COVID-19
Innovation Pharma is developing Brilacidin for COVID-19 under Fast Track designation from the U.S. Food and Drug Administration (FDA), and currently is enrolling patients in a Phase 2 clinical trial of Brilacidin for treatment of moderate-to-severe COVID-19 in hospitalized patients (see NCT04784897). Upon recently completing a scheduled review of interim safety data from the trial, an independent Data Monitoring Committee (DMC) recommended increasing the dosing regimen of Brilacidin from 3 days to 5 days of treatment, which may maximize therapeutic benefits and provide a comparison with 5-day remdesivir (Veklury™), currently the only FDA-approved treatment for COVID-19. The annual global antiviral drug market is estimated to reach $44 billion by 2026.
I live in Ontario and we are currently in a lockdown until at least May 20th and it will probably get extended because that is before our long weekend. They were talking about implementing a curfew. Ugh! This has been at least our fourth/fifth lockdown since it got here in 2020.
The world needs Brilacidin to work and work fast...
Go Leo - Make this happen!
Agreed, great post!
Very nicely put. Waiting and watching the chart as well. Thought we'd see a deeper dip but anything can happen at any moment.
Well grounded thoughts from JFM.....
We are waiting for results for CURRENT Covid-19 Clinical Trials...some would have you believe "WAITING" = failure
"Waiting" IS THE PROCESS...and as ALL OTHER POTENTIAL THERAPEUTICS FAIL...Brilacidin becomes the last highly probable Therapeutic candidate to be determined SAFE and EFFICACIOUS against...NOT ONLY COVID-19, but also IMO:
1. All Covid-19 Variants
2. Pan-coronaviruses (additional and new RBL testing independent of IPIX)
3. Alpha-Virus efficacy (New RBL testing)
Of course PR's indicate more good news coming on either OM or UC or both.
for those who choose to listen to meritless generalizations ...I am looking forward to their departing of their shares ... 500,000 shares order placed...(level II)
Anxiously awaiting filling !
Great post JFM (in its entirety).
Post sites article in Nature (journal) that states several "substances" with very low SI showed "little" effect on virus replication OR showed SEVERE ADVERSE EFFECT in human patients....
1. WHY WOULDN"T THEY SHOW "LITTLE" effect...THEY HAD VERY LOW SI SCORES!!! IN FACT, All these "Substances" COMBINED did not match BRILACIDIN'S SI SCORE *426*. TO COMPARE THESE SUBSTANCES TO OR ANY SUBSTANCE in competition with BRILACIDIN...the substance being compared (which there are NONE) would be "SI" Score of 426...THERE ARE NO OTHERS! So, the comparative statement is comparing rotten apples to juicy oranges.
2. AGAIN...BRILACIN's SI's 426 SCORE is greater than ALL THOSE SUBSTANCES SI SCORE COMBINED and they showed "Little effect", therefore it is reasonable to expect Brilacidin, with 10X SI score of substances cited,...to show SIGNIFICANTLY MORE EFFECT on Covid viral suppression.
3. SAE COMPARISON? as is noted in quote...those OTHER SUBSTANCES "...led to SAE (severe adverse events and side effects) in human patients."...OK...but BRILACIDIN throughout PHASE II Clinical Trials for 5 Different Indications...BRILACIDIN has NEVER CAUSED a single SAE.
So what these "other" substances do it totally irrelevant to Brilacidin.
Quote:
"...several substances like Remdesivir, Lopinavir and Chloroquine were reported to repress viral replication in vitro. However, these compounds showed little effect on virus replication or led to severe adverse side effects in human patients." Bottom line: is that the
in vitro assays in cells did not predict clinical behavior.
Conclusion:
SUBSTANCES WITH Small SI SCORES showed small SUPRESSION of VIRAL SUPPRESSION in Clinical Trials...therefore Substances (Brilacidin) with EXTREMELY HIGH (HIGHEST) SI SCORE OF POTENTIAL THERAPEUTICS ... will likely demonstrate in Clinical Trials EXTREMELY HIGH VIRAL SUPPRESSION in current clinical trials...compared to the substances sited.
Thank you for providing a post to further demonstrate the GREAT POTENTIAL of BRILACIDIN vs. Covid-19 IMO soon to be demonstrated in the current Clinical Trials!
Great post! Thanks
Go Leo & IPIX!
B-COVID Is A Big Deal
Today's national news that reports worldwide COVID-19 deaths just passed 3M with 12,000 deaths occurring everyday. Additionally, while only a small percentage of the world is vaccinated against COVID-19, variants, manufacturing/supply chain, import/export and intellectual property issues, all threaten to slow the worldwide vaccination rate even further.
https://www.nature.com/articles/d41586-021-00727-3
An effective COVID-therapeutic that is among the first to prove that it keeps patients from dying from COVID will be very valuable to the non-vaccinated populations of the world and will generate billions in sales. Governments and global organizations are waiting to buy for one big obvious reason. The ultimate goal is to stop people from dying from COVID with or without vaccine, but B-COVID might also have a "prophylactic" property as well. This property, if possessed, would greatly increase B-COVID's usage and sales.
Quote:
During the global COVID-19 pandemic, we selectively formed new external industry partnerships, including this opportunity to research a drug candidate like Brilacidin,” said Aarthi Narayanan, PhD, Associate Professor of Systems Biology in Mason’s College of Science. “In testing at GMU’s BSL-3 lab, we showed that Brilacidin potently inhibits SARS-CoV-2 in vitro against the live virus. Beyond exhibiting treatment potential for those already infected by COVID-19, Brilacidin’s ability to disrupt viral integrity and block viral entry indicates it has the added potential to prevent infection, upon appropriate formulation, as a prophylactic. I look forward to working with Innovation to investigate further Brilacidin’s antiviral properties,” Narayanan added.
http://www.ipharminc.com/press-release/2020/10/30/innovation-pharmaceuticals-and-george-mason-university-announce-public-release-of-laboratory-testing-results-demonstrating-brilacidins-covid-19-treatment-potential
The evidence suggest B-COVID is on the brink of becoming a major breakthrough as an effective-therapeutic drug against COVID-19. Evidence that range from a "molecular screening of 11,552 compounds" to a "426 SI". Additionally, George Mason University's (GMU) College of Science is behaving as if they are trying to enhance their reputation through the promising research they developed on "B" for COVID, which made them believe that "B" is likely the answer to COVID as well as other viral indications.
Based on the evidence, I fully expect B-COVID's P-2 to produce results good enough to qualify for a EUA. If this occurs then I think it will be a wake-up call for BP players in the Antiviral Drug Market. Players like Gilead Sciences, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, AbbVie, Johnson & Johnson and Bristol-Myers Squibb. "These industry leaders are adopting various inorganic growth strategies to gain market share and sustainable competitive advantage." (Note: Inorganic growth is the rate of growth of business, sales expansion etc. by increasing output and business reach by acquiring new businesses by way of mergers, acquisitions and take-overs.)
https://www.gminsights.com/industry-analysis/antiviral-drugs-market?gclid=Cj0KCQjwpdqDBhCSARIsAEUJ0hO0Ug6sjNrM28NQKlDLeg3DsGoQ1BfEdNCVjjimnPtY9BjxMw2-KNgaAmfoEALw_wcB
If IPIX has any suitors my guess is that it is one of the above. These potential suitors will not overlook the billion$ associated with an effective COVID therapeutic and the fact that those billion$ in sales will not take years to ramp up. No pharmaceutical sales force needed. Governments and global organizations will buy in bulk and distribute.
Additionally, GMU will be testing B's efficacy against their frozen inventory of "virological vermin", the first of which I hope is the enveloped virus that causes HIV because of the $44B 2020 market value for antiviral drugs, HIV drugs account for $30B.
Furthermore, between 2021 and 2027 the Antiviral Drug Market is projected to grow at a CAGR of 1.6%, while the coronavirus infection segment is projected to grow at a CAGR of 6.4%.
https://www.gminsights.com/industry-analysis/antiviral-drugs-market?gclid=Cj0KCQjwpdqDBhCSARIsAEUJ0hO0Ug6sjNrM28NQKlDLeg3DsGoQ1BfEdNCVjjimnPtY9BjxMw2-KNgaAmfoEALw_wcB
Unlike the development of B as a broad-spectrum viral and other B indications that will take years, B-COVID represents the HERE AND THE NOW, whose potential short term sales could produce revenues large enough to give IPIX the financial independence it needs to develop its pipeline in a time and manner of its' choosing.
All of the reasons I've stated above that will probably attract BP are also reasons I believe Leo will not be making any deals regarding B-COVID. Some here seem to think that all BP has to do is come-a-callin' and Leo will cave. IMO, Leo is still looking to maximize the value of our pipeline and nothing does that better than having one-two or more billion-dollar indications producing reliable and predictable revenues. I think current market conditions have given Leo the visibility he needed to see the path he needs to take to realize his strategy of maximizing the value of our pipeline.
Message in reply to:
COVID-19 Front-Burner, Broad-Spectrum Anti-viral Back-Burner, Sheer, Genius Leo
Quote:
Company advancing Brilacidin as a next-generation broad-spectrum antiviral for the treatment of common colds and deadly coronavirus infections
.... Research shows Brilacidin exerted potent in vitro inhibition of multiple strains of H-CoVs. On completion of testing, the H-CoV findings are expected to be submitted for peer-review publication. The Company is evaluating these data alongside previously obtained SARS-CoV-2 data, strategizing with its scientific advisors and consultants, to develop Brilacidin as a “pan-coronavirus” therapeutic.
http://www.ipharminc.com/press-release/2020/11/30/innovation-pharmaceuticals-covid-19-clinical-trial-to-support-additional-development-of-brilacidin-as-a-pan-coronavirus-therapeutic
I believe this quote signaled Leo's change FROM IBD, as the lead area of focus for Brilacidin, TO Anti-Viral Drug Therapy. Here's why:
Quote:
The global anti-viral drug therapy market reached a value of nearly $46,456.4 million [=$46.4B] in 2019, having increased at a compound annual growth rate (CAGR) of 5.0% since 2015. The market is expected to grow from $46,456.4 million [=$46.4B] in 2019 to $ 61,571.9 million [=$61.5B] in 2020 at a rate of 32.5%. The growth is mainly due to the increase in number of COVID-19 cases. The market is then expected to grow at a CAGR of 8.3% from 2021 and reach $74,385.9 million [=$74.3B] in 2023. The market is expected to reach $ 87,230.5 million [=$87.2B] in 2025, and $ 130,125.3 million [=$130.1B] in 2030. [equivalency added]
https://www.businesswire.com/news/home/20210210005504/en/Global-Anti-Viral-Drug-Therapy-Market-2020-to-2030---Opportunities-and-Strategies-with-COVID-19-Implications-and-Growth---ResearchAndMarkets.com
The beauty of the development of 'B' for AVDT is that the researchers are excited about doing the "broad-spectrum" research based on what they observed in the B-COVID research. Additionally, the pandemic has motivated governments to invest more money in research for vaccines and AVDTs.
By comparison:
The global inflammatory bowel disease treatment market size is expected to reach USD 22.4 billion by 2026, according to a new report by Grand View Research, Inc., registering a 4.4% CAGR during the forecast period. Increasing prevalence and incidence of Crohn’s disease and ulcerative colitis is one of the major factors contributing to the market.
https://www.grandviewresearch.com/press-release/global-inflammatory-bowel-disease-ibd-treatment-market?utm_source=blog.goo.ne.jp&utm_medium=referral&utm_campaign=Vrushali_7Aug_hc_InflammatoryBowelDiseaseTreatmentMarket_pr&utm_content=Content
Sometimes following Leo's thinking is as simple as following the money. In 2030, the projected anti-viral drug therapy (AVDT) market size will be nearly 6-times the market size of IBD in 2026, suggesting that between 2021 -2030, the AVDT market will be the much, much, more lucrative area of the two.
Normally, I would say given these facts and projections, IBD must take a backseat to AVDT. BUT, if you will click on the reference post# above, you can read why I believe B-COVID will be able to provide all the financing needed for development of AVDT, IBD and the rest of IPIX's pipeline...simultaneously.
Loanranger...both you and SUN refer to SE (side effects) of Brilacidin in clinical trials...and SUN asserts they occur 50% of the time...but neither of you can not come up with "one" CITED IN FDA CLINICAL TRIALS for the 5 separate indications involving Brilacidin prior Clinical Trials.
So are you saying there were "SE" cited by FDA in some or all of the Clinical Trials (Phase I anc Phase II)? if so WHAT WERE THEY and if so Show how they occurred in over 50% of the candidate...
You can't, because Brilacidin SE were never asserted or noted by the FDA...There were NO SE asserted by FDA and the statement and inference is totally false!
Courtesy of JFM!
There have been voluminous posts admitting to the "total confusion" regarding Leo's stock positions and dispositions, involving Class A stock, Class B stock, including sales, exchanges, conversions etc.
From that "cloudiness" there seems to be an inference that their personal confusion and lack of their "personal" understanding of what they are reading justifies the raises of issues and suspicion of "nefarious conduct" by Leo...
I checked with a CPA from a Public Accounting firm...the comment to me was "Its a nothing burger" ... the questions asked reflect a basic lack of understanding of public accounting 101. "Nothing improper there...just ignorance of those questioning...which if they asked the SEC (and if the party even received a response), the party questioning would display their ignorance with their questions and receive the same response."
All this commentary, even though IPIX has Public Accounting firm, and SEC attorneys who review regulatory filings and clears them prior to filing!
Great post JFM and thanks!
Release!
Innovation Pharma’s Broad Spectrum Antiviral Drug Candidate Brilacidin Highlighted in Biodefense and Infectious Diseases COVID-19 Presentation
WAKEFIELD, MA – April 14, 2021 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced that Brilacidin, the Company’s defensin-mimetic drug candidate, was featured in the “Mason Science Series: Rising to the National and International COVID-19 Challenge,” a presentation of George Mason University.
The presentation covers the latest research of Dr. Aarthi Narayanan, a faculty member in George Mason’s National Center for Biodefense and Infectious Diseases, and her team’s (and associated teams) efforts, which are geared towards the development of therapeutics and vaccines against SARS-CoV-2, including Brilacidin. A video of Dr. Narayanan’s presentation can be accessed at the link below. Discussion of Brilacidin begins at approximately the 40-minute mark.
• Mason Science Series: Rising to the National and International COVID-19 Challenge - YouTube
Dr. Narayanan has been leading ongoing research assessing Brilacidin’s broad spectrum antiviral potential, with preliminary in vitro data showing Brilacidin potently inhibits both coronaviruses and alphaviruses. As previously released, these data will serve as the basis for an Oral Presentation on Brilacidin’s antiviral properties to be delivered at the American Society of Virology’s 40th Annual Meeting (ASV 2021), taking place July 19-23, 2021.
Variants of the SARS-CoV-2 virus continue to pose a significant challenge in the COVID-19 pandemic. Today, the B.1.1.7 variant, first discovered in the United Kingdom, is the most common variant in the U.S., according to Centers for Disease Control and Prevention (CDC) Director, Dr. Rochelle Walensky. Due to a potential lessened therapeutic effect against variants, monoclonal antibody treatments have been called into question. Eli Lilly, for example, recently stopped supplying bamlanivimab as a solo therapy for treatment of COVID-19. Variants are showing a similar ability to reduce the effectiveness of COVID-19 vaccines, with safety concerns associated with vector-based vaccines surfacing.
To help satisfy a large unmet need in the antiviral therapeutics area, the Company is developing Brilacidin as a potential novel broad spectrum antiviral drug.
I really like this press release!
If Brilacidin goes on to realize its promise as a broad spectrum antiviral, the potential benefits to patients and shareholders for this drug would likely be greater than I or anyone could have ever imagined.”
http://www.ipharminc.com/press-release/2021/4/7/innovation-pharma-announces-brilacidin-abstract-accepted-for-oral-presentation-at-the-american-society-for-virologys-annual-meeting
Go Leo & IPIX!
Innovation Pharma Announces Brilacidin Abstract Accepted for Oral Presentation at the American Society for Virology’s Annual Meeting
Growing body of in vitro data support Brilacidin’s potential as a broad-spectrum inhibitor of viruses
Brilacidin is currently undergoing Phase 2 clinical testing against COVID-19 in hospitalized patients
WAKEFIELD, MA – April 7, 2021 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced that antiviral data related to Brilacidin, the Company’s defensin-mimetic drug candidate, has been accepted for an Oral Presentation at the American Society of Virology’s 40th Annual Meeting (ASV 2021), taking place July 19-23, 2021.
The presentation—“Brilacidin, a Host Defense Protein/Peptide Mimetic, Shows Potential as Broad Spectrum Inhibitor of Acutely Infectious Viruses”—is based on ongoing independent laboratory research being conducted by scientists at George Mason University (GMU)/National Center for Biodefense and Infectious Diseases (NCBID). Brilacidin was shown to exhibit a potent inhibitory effect on SARS-CoV-2, the novel coronavirus responsible for COVID-19, as well as different types of alphaviruses, in cell culture. Further details on the Brilacidin ASV 2021 presentation will be forthcoming.
Most experts are of the opinion that, at best, COVID-19 is going to be endemic for years to come as SARS-CoV-2 continues to mutate and circulate in different pockets around the world, effectively joining a growing list of viruses that remain a costly bane on society globally, both in lives and dollars lost.
“An effective broad-spectrum antiviral is largely absent in medicine today,” commented Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. “So it is extremely rewarding to see Brilacidin exhibit consistent in vitro inhibition against coronaviruses and alphaviruses. These current research findings have us believe Brilacidin’s broad spectrum potential may even go farther, extending into other virus families, due to its unique properties as a defensin-mimetic. The ASV 2021 presentation provides an ideal forum for us to showcase the pre-clinical antiviral activity of Brilacidin, which we hope to see duplicated in our ongoing Phase 2 clinical trial of Brilacidin in hospitalized COVID-19 patients. If Brilacidin goes on to realize its promise as a broad spectrum antiviral, the potential benefits to patients and shareholders for this drug would likely be greater than I or anyone could have ever imagined.”
IMO...trials will be expedited and be over quickly...and done where ever they can be completed the fastest. If we get the results commensurate with the GMU RBL results...it opens up ALL Virus research, development and associated opportunities...IMO ALL OPPORTUNITIES !!!
Reading through all the PRs...and putting them together...IMO interest by the scientific/medical community in Brilacidin is beyond Covid-19 and...is into the "Holy Grail" aspect of Brilacidin functionality...(even before current CT is over).
TIAB speculated: “MERS and SARS and other coronaviruses might be B targets. It was hinted there was work being done."
IMO...it’s MORE THAN A HINT!
This reference in PR AGAIN to RBL continued Testing (in lab other than GMU) with focus on Pan-Coronaviruses...which is independent of the IPIX, HAS POPPED UP AGAIN...IMO...LEO is indicating at least one highly focused RBL is continuing to test Brilacidin against ALL VIRUSES.
These independent RBLs do not report to the company about their "findings", but they do publish independent "Peer Reviewed" articles about those findings and the results of a company's compounds (in our case...Brilacidin) that they study and test.
...They also seek and receive "grants" for themselves under generic titles as in "Compounds to treat all Pan-coronaviruses"... (not overtly stating "Brilacidin" as their target). These Grants are separate and apart from the company's (they want all the money, control, and bragging rights) ...from CDC, BARDA, NIH, DOD etc...
Last PR appeared to indicate...BRILACIDIN...is in the crosshairs of a specialized RBL focusing on Pan-coronaviruses. We will not know when Brilacidin testing on other Pan-coronaviruses will be complete, nor when results ready for public consumption...but IMO as an effective and broad range antiviral/antibacterial (which DeGrado has always contended), Brilacidin/Covid-19 challenge and success, alone becomes chump change for the Brilacidin horizon.
Those shorts/impatient will likely disparage the above ...but "investors" will be patient and savor the opportunity. IMO Investors will receive a multiple of MORE for what they even imagined...if trial results confirm DeGrado's belief...I am more confident in DeGrado's judgment than uninformed posters...
Great post Justfactsmam!
Good Friday, April 2 2021
Go Leo & IPIX!
Lily... why 3:59?